TxCell names François Meyer as CEO
TxCell SA, a biotechnology company developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need, announced the appointment of Dr. François Meyer as its chief executive officer.
Dr. François Meyer, PhD, has more than 25 years of pharmaceutical and biotechnology experience. During the early part of his career, he held various executive positions in R&D at Ciba-Geigy Pharma, where he headed the Molecular Genetics department in the newly formed Biotechnology division and at Sandoz Pharma, where he led the Gene and Cell Therapy business. After joining Rhone Poulenc Rorer in 1996, where he first headed R&D at Gencell, a biotechnology division of Rhone Poulenc Rorer, he was promoted to head of Global Research in 1998 and became head of R&D at Aventis Pharma, France after the merger with Hoechst in 2000. Lately he was CEO of Centelion until 2006, a biopharmaceutical affiliate company of Aventis Pharma. He has been member of the board of directors of several privately owned biopharmaceutical companies in the US and in Europe and is currently member of the supervisory board of Amsterdam Molecular Therapeutics (NL). He graduated from the Swiss Federal Institute of Technology (ETHZ), in Zurich. He received his PhD from the Institute for Molecular Biology at the University of Zurich.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
